NCT03926052View on ClinicalTrials.gov

Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 7, 2019

Primary Completion Date

November 18, 2024

Study Completion Date

November 18, 2024

Conditions

Binge-Eating DisorderObesity

Interventions

DRUG

Lisdexamfetamine Dimesylate

Participants randomly assigned to this arm will receive 12 weeks of LDX medication.

DRUG

Placebo

Participants randomly assigned to this arm will receive 12 weeks of an inactive placebo.

Trial Locations (1)

06510

Yale Department of Psychiatry, New Haven

All Listed Sponsors

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER

NCT03926052 - Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment | Biotech Hunter | Biotech Hunter